ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.446,94
-0,03%
S&P 500
6.101,24
-0,29%
US Dollar vs BRL
5,9325
0,33%
Bitcoin
99.398,72
-3,17%
Brent Oil
77,065
-0,16%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Compugen Ltd (CGEN)

  7. Compugen Ltd (CGEN) Notícias

CGEN

Compugen (CGEN)

Compugen Ltd
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CGEN
DataHoraFonteTítuloCódigoCompanhia
08/01/202509:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CGENCompugen Ltd
08/01/202509:00PR Newswire (US)Compugen Announces First Patient Dosed in Phase 1 Clinical Trial to Evaluate COM503 as Monotherapy and in Combination with Zimberelimab in Advanced Solid TumorsNASDAQ:CGENCompugen Ltd
27/11/202409:00PR Newswire (US)Compugen Expands its Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use of COM902 (reduced Fc anti-TIGIT) with anti-PD-1 and anti-PVRIG AntibodiesNASDAQ:CGENCompugen Ltd
12/11/202409:00PR Newswire (US)Compugen Reports Third Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
11/11/202409:00PR Newswire (US)Compugen to Participate in Stifel 2024 Healthcare ConferenceNASDAQ:CGENCompugen Ltd
05/11/202411:00PR Newswire (US)Compugen to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024NASDAQ:CGENCompugen Ltd
29/10/202408:00PR Newswire (US)Compugen to Release Third Quarter 2024 Financial Results on Tuesday, November 12, 2024NASDAQ:CGENCompugen Ltd
07/10/202408:00PR Newswire (US)Compugen to Present New Clinical Data at SITC 2024NASDAQ:CGENCompugen Ltd
09/09/202408:00PR Newswire (US)Compugen to Present at Single Cell Genomics 2024 ConferenceNASDAQ:CGENCompugen Ltd
29/08/202408:00PR Newswire (US)Compugen to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:CGENCompugen Ltd
06/08/202408:00PR Newswire (US)Compugen Reports Second Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
29/07/202408:00PR Newswire (US)Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid TumorsNASDAQ:CGENCompugen Ltd
23/07/202408:00PR Newswire (US)Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024NASDAQ:CGENCompugen Ltd
17/06/202408:00PR Newswire (US)Compugen to Present at Upcoming Antibody Industrial SymposiumNASDAQ:CGENCompugen Ltd
30/05/202408:00PR Newswire (US)Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating RilvegostomigNASDAQ:CGENCompugen Ltd
20/05/202408:00PR Newswire (US)Compugen Reports First Quarter 2024 ResultsNASDAQ:CGENCompugen Ltd
20/05/202407:59IH Market NewsU.S. Index Futures Edge Slightly Higher in Pre-Market Trading, Oil Prices DipNASDAQ:CGENCompugen Ltd
16/05/202408:00PR Newswire (US)Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic PotentialNASDAQ:CGENCompugen Ltd
15/05/202408:00PR Newswire (US)Compugen Appoints David Silberman as Chief Financial OfficerNASDAQ:CGENCompugen Ltd
06/05/202408:00PR Newswire (US)Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024NASDAQ:CGENCompugen Ltd
25/04/202408:00PR Newswire (US)Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024NASDAQ:CGENCompugen Ltd
10/04/202408:00PR Newswire (US)Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503NASDAQ:CGENCompugen Ltd
03/04/202408:00PR Newswire (US)Compugen to Participate in Two Upcoming Investor ConferencesNASDAQ:CGENCompugen Ltd
11/03/202408:00PR Newswire (US)Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer ImmunotherapyNASDAQ:CGENCompugen Ltd
06/03/202409:00PR Newswire (US)Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024NASDAQ:CGENCompugen Ltd
05/03/202418:06Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:CGENCompugen Ltd
05/03/202409:00PR Newswire (US)Compugen Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:CGENCompugen Ltd
05/03/202408:05IH Market NewsU.S. Futures Dip, Crude Oil FluctuatesNASDAQ:CGENCompugen Ltd
26/02/202409:00PR Newswire (US)Compugen to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:CGENCompugen Ltd
20/02/202409:00PR Newswire (US)Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024NASDAQ:CGENCompugen Ltd
 Apresentando as notícias mais relevantes sobre:NASDAQ:CGEN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados